<DOC>
	<DOCNO>NCT00438841</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cyclophosphamide dexamethasone , work different way stop growth cancer cell , either kill cell stop dividing . Thalidomide may stop growth cancer cell block blood flow cancer . Giving bortezomib together cyclophosphamide , dexamethasone , thalidomide may kill cancer cell . PURPOSE : This phase II trial study well give bortezomib together cyclophosphamide , dexamethasone , thalidomide work treat patient newly diagnose , previously untreated multiple myeloma .</brief_summary>
	<brief_title>Bortezomib , Cyclophosphamide , Dexamethasone , Thalidomide Treating Patients With Newly Diagnosed , Previously Untreated Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient newly diagnose , previously untreated multiple myeloma treat bortezomib , cyclophosphamide , dexamethasone , thalidomide . Secondary - Determine safety tolerability regimen patient . OUTLINE : This open-label , multicenter study . Patients receive bortezomib IV day 1 , 4 , 8 , 11 ; cyclophosphamide IV day 1 8 course 1-3 ; oral thalidomide daily day 1-21 begin course 4 ; dexamethasone IV orally daily day 1 , 2 , 4 , 5 , 8 , 9 , 11 , 12 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 43 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma meeting 1 follow criterion : Monoclonal immunoglobulin spike serum electrophoresis ( IgG &gt; 3.5 g/dL IgA &gt; 2.0 g/dL ) kappa lambda light chain excretion &gt; 1 g/day 24hour urine protein electrophoresis AND meet follow criterion : Bone marrow plasmacytosis ( 1030 % plasma cell ) Lytic bone lesion Monoclonal immunoglobulin less magnitude present bone marrow plasmacytosis ( 1030 % plasma cell ) AND meet follow criterion : Lytic bone lesion IgM &lt; 50 mg/dL , IgA &lt; 100 mg/dL , IgG &lt; 600 mg/dL Bone marrow plasmacytosis ( &gt; 30 % plasma cell ) plasmacytoma tissue biopsy AND meet follow criterion : Monoclonal immunoglobulin less magnitude present Lytic bone lesion IgM &lt; 50 mg/dL , IgA &lt; 100 mg/dL , IgG &lt; 600 mg/dL FreeLite test abnormal kappa : lambda light chain ratio abnormal Symptomatic disease require treatment Documented relate organ tissue involvement , present Measurable disease , define 1 following : Monoclonal immunoglobulin spike serum electrophoresis ≥ 1 g/dL and/or urine monoclonal immunoglobulin spike ≥ 200 mg/day Abnormal FreeLite testing ( nonsecretors ) Patients nonsecretory disease must meet either follow criterion measurability : Has measurable protein FreeLite test Untreated soft tissue plasmacytoma and/or evaluable disease bone marrow Newly diagnose , previously untreated disease No POEMS syndrome ( i.e. , plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein [ Mprotein ] , skin change ) No plasma cell leukemia PATIENT CHARACTERISTICS : Karnofsky performance status 50100 % Platelet count ≥ 100,000/mm³ ( ≥ 50,000/mm³ bone marrow extensively infiltrate ) Extensive infiltration define &gt; 50 % myeloma cell plasma cell Hemoglobin ≥ 8.5 g/dL Absolute neutrophil count ≥ 1,500/mm³ AST ALT ≤ 2 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN ( unless clearly related disease ) Creatinine clearance ≥ 20 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use 2 method effective contraception ≥ 4 week prior begin treatment , , ≥ 4 week completion study treatment No impair kidney function require dialysis No uncontrolled infection No HIV positivity No known active hepatitis B C No cardiovascular disease include , limited , follow : Myocardial infarction within past 6 month New York Heart Association class IIIV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Clinically significant pericardial disease Acute ischemic active conduction system abnormality EKG No history allergic reaction compound contain mannitol , bortezomib , cyclophosphamide No second malignancy require concurrent treatment No serious medical psychiatric illness would preclude study compliance No peripheral neuropathy ≥ grade 1 PRIOR CONCURRENT THERAPY : No prior chemotherapy , immunotherapy , vaccine therapy , therapeutic dos steroid , agent treatment active myeloma Drugs give prevent onset myeloma allow Bisphosphonates hypercalcemia short course corticosteroid hypercalcemia cord compromise allow Prior local radiotherapy without brief exposure steroid allow More 4 week since prior concurrent radiotherapy Spot radiotherapy ≤ 3 vertebra allow No concurrent steroid &gt; 10 mg prednisone daily ( equivalent ) medical condition ( e.g. , asthma , systemic lupus erythematosus , rheumatoid arthritis ) No concurrent chemotherapy investigational agent Concurrent daily acetylsalicylic acid require course 46 study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>